Zacks Research Weighs in on AngioDynamics FY2028 Earnings

Key Points

• Zacks Research predicts AngioDynamics will report an EPS of ($0.04) for FY2028, an improvement from the consensus estimate of ($0.37) for the current fiscal year.
• Several brokerages have issued positive ratings for AngioDynamics, with Lake Street Capital setting a target price of $24.00 and Canaccord Genuity raising their target to $17.00.
• AngioDynamics reported a quarterly revenue increase of 13.0% year-over-year, with actual earnings of ($0.03) per share, outperforming analysts' expectations.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Zacks Research issued their FY2028 EPS estimates for shares of AngioDynamics in a note issued to investors on Tuesday, August 5th. Zacks Research analyst R. Department expects that the medical instruments supplier will earn ($0.04) per share for the year. The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share.

A number of other brokerages have also recently issued reports on ANGO. Lake Street Capital initiated coverage on shares of AngioDynamics in a report on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of AngioDynamics in a report on Wednesday, July 16th. Finally, Canaccord Genuity Group increased their price target on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a report on Wednesday, July 16th.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $8.67 on Wednesday. The firm's 50-day moving average is $9.74 and its 200-day moving average is $9.87. The stock has a market cap of $352.26 million, a price-to-earnings ratio of -10.45 and a beta of 0.67. AngioDynamics has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.09. The company had revenue of $80.16 million for the quarter, compared to analysts' expectations of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. AngioDynamics's quarterly revenue was up 13.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.06) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ANGO. American Century Companies Inc. raised its holdings in AngioDynamics by 22.1% in the 4th quarter. American Century Companies Inc. now owns 67,942 shares of the medical instruments supplier's stock valued at $622,000 after acquiring an additional 12,306 shares during the period. JPMorgan Chase & Co. grew its position in shares of AngioDynamics by 46.0% during the 4th quarter. JPMorgan Chase & Co. now owns 807,483 shares of the medical instruments supplier's stock worth $7,397,000 after purchasing an additional 254,322 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its position in shares of AngioDynamics by 293.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 352,544 shares of the medical instruments supplier's stock worth $3,229,000 after purchasing an additional 263,034 shares in the last quarter. Geode Capital Management LLC grew its position in shares of AngioDynamics by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 974,302 shares of the medical instruments supplier's stock worth $8,927,000 after purchasing an additional 13,535 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of AngioDynamics by 35.4% during the 4th quarter. Wells Fargo & Company MN now owns 23,715 shares of the medical instruments supplier's stock worth $217,000 after purchasing an additional 6,200 shares in the last quarter. 89.43% of the stock is owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.